RSI Alert: OncoMed Pharmaceuticals (OMED) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Thursday, shares of OncoMed Pharmaceuticals Inc. ( OMED) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $8.19 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 59.1. A bullish investor could look at OMED's 29.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of OMED shares:

START SLIDESHOW:
Find out what 9 other oversold stocks you need to know about »

OncoMed Pharmaceuticals Inc. 1 Year Performance Chart

Looking at the chart above, OMED's low point in its 52 week range is $8.07 per share, with $23.98 as the 52 week high point — that compares with a last trade of $8.22.

More from Stocks

Starbucks Just Revealed Some of the Most Worrying Data in Its History

Starbucks Just Revealed Some of the Most Worrying Data in Its History

Salesforce Is Hitting on All Cylinders as Shares Notch an All-Time High

Salesforce Is Hitting on All Cylinders as Shares Notch an All-Time High

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Why GE's Stock Has Fallen 15% in the Last 30 Days

Why GE's Stock Has Fallen 15% in the Last 30 Days

Banks Prepare to Up Shareholder Payouts By $30 Billion

Banks Prepare to Up Shareholder Payouts By $30 Billion